Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity

About the Report

About the Report

Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of USD 33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.

Highlighted with 35 tables and 54 figures, this 110-page report Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country.

 

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Immunomodulators

o Copaxone

o Avonex/Plegridy

o Gilneya

o Tysabri

o Betaseron/Extavia

o Tecifidera

o Rebif

o Ampyra

o Other Immunomodulators

Immunosuppressants

o Aubagio

o Lemtrada

o Ocrelizumab

o Zinbryta

o Other Immunosuppressants

 

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Monoclonal Antibodies

Interferon Beta

Sphingosine 1 Phosphate Receptor Modulators

Mixed Polymers

NF-?B Inhibitor

Pyrimidine Synthesis Inhibitor

Corticosteroids

Adrenocorticotropic Hormone

Other Drug Classes

 

Based on Drug Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Large-molecule Drugs

Small-molecule Drugs

 

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Oral Administration

Parenteral Administration

 

Based on MS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Relapsing-remitting MS (RRMS)

Primary-progressive MS (PPMS)

Secondary-progressive MS (SPMS)

Progressive-relapsing MS (PRMS)

 

Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

 

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbvie, Inc.

Acorda Therapeutics Inc.

Bayer AG

Biogen Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Merck KgaA

Mylan NV

Novartis AG

Pfizer Inc.

Sanofi SA

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbvie, Inc.

Acorda Therapeutics Inc.

Bayer AG

Biogen Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Merck KgaA

Mylan NV

Novartis AG

Pfizer Inc.

Sanofi SA

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 20

2.1.2 Impact of COVID-19 on the Market 22

2.2 Major Growth Drivers 24

2.3 Market Restraints and Challenges 29

2.4 Emerging Opportunities and Market Trends 33

2.5 Porter's Fiver Forces Analysis 37

3 Segmentation of Asia Pacific Market by Drug Type 41

3.1 Market Overview by Drug Type 41

3.2 Immunomodulators 43

3.3 Immunosuppressants 45

4 Segmentation of Asia Pacific Market by Drug Class 47

4.1 Market Overview by Drug Class 47

4.2 Monoclonal Antibodies 49

4.3 Interferon Beta 50

4.4 Sphingosine 1 Phosphate Receptor Modulators 51

4.5 Mixed Polymers 52

4.6 NF-?B Inhibitor 53

4.7 Pyrimidine Synthesis Inhibitor 54

4.8 Corticosteroids 55

4.9 Adrenocorticotropic Hormone 56

4.10 Other Drug Classes 57

5 Segmentation of Asia Pacific Market by Drug Category 58

5.1 Market Overview by Drug Category 58

5.2 Large-molecule Drugs 60

5.3 Small-molecule Drugs 61

6 Segmentation of Asia Pacific Market by Route of Administration 62

6.1 Market Overview by Route of Administration 62

6.2 Oral Administration 64

6.3 Parenteral Administration 65

7 Segmentation of Asia Pacific Market by MS Type 66

7.1 Market Overview by MS Type 66

7.2 Relapsing-remitting MS (RRMS) 68

7.3 Primary-progressive MS (PPMS) 69

7.4 Secondary-progressive MS (SPMS) 70

7.5 Progressive-relapsing MS (PRMS) 71

8 Segmentation of Asia Pacific Market by Distribution Channel 72

8.1 Market Overview by Distribution Channel 72

8.2 Hospital Pharmacies 74

8.3 Retail Pharmacies 75

8.4 Online Pharmacies 76

9 Asia-Pacific Market 2020-2027 by Country 77

9.1 Overview of Asia-Pacific Market 77

9.2 China 80

9.3 Japan 82

9.4 India 85

9.5 Australia 87

9.6 South Korea 89

9.7 Rest of APAC Region 91

10 Competitive Landscape 93

10.1 Overview of Key Vendors 93

10.2 New Product Launch, Partnership, Investment, and M&A 96

10.3 Company Profiles 97

Abbvie, Inc. 97

Acorda Therapeutics Inc. 99

Bayer AG 100

Biogen Inc. 101

Bristol-Myers Squibb Company 102

F. Hoffmann-La Roche Ltd. 103

Merck KgaA 104

Mylan NV 105

Novartis AG 106

Pfizer Inc. 107

Sanofi SA 108

Teva Pharmaceutical Industries Ltd. 109

RELATED REPORTS 110


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16

Figure 4. Asia Pacific Multiple Sclerosis Drugs Market, 2017-2027, USD mn 19

Figure 5. Impact of COVID-19 on Business 22

Figure 6. Primary Drivers and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 24

Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27

Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27

Figure 9. Primary Restraints and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 29

Figure 10. Investment Opportunity Analysis 34

Figure 11. Porter's Fiver Forces Analysis of Asia Pacific Multiple Sclerosis Drugs Market 37

Figure 12. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41

Figure 13. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value (USD mn) and Share (%) 42

Figure 14. Asia Pacific Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, USD mn 43

Figure 15. Asia Pacific Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, USD mn 45

Figure 16. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48

Figure 17. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Class, Value (USD mn) and Share (%) 48

Figure 18. Asia Pacific Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, USD mn 49

Figure 19. Asia Pacific Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, USD mn 50

Figure 20. Asia Pacific Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, USD mn 51

Figure 21. Asia Pacific Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, USD mn 52

Figure 22. Asia Pacific Multiple Sclerosis Drugs Market: NF-?B Inhibitor, 2017-2027, USD mn 53

Figure 23. Asia Pacific Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, USD mn 54

Figure 24. Asia Pacific Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, USD mn 55

Figure 25. Asia Pacific Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, USD mn 56

Figure 26. Asia Pacific Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, USD mn 57

Figure 27. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58

Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Category, Value (USD mn) and Share (%) 59

Figure 29. Asia Pacific Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, USD mn 60

Figure 30. Asia Pacific Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, USD mn 61

Figure 31. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62

Figure 32. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value (USD mn) and Share (%) 63

Figure 33. Asia Pacific Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, USD mn 64

Figure 34. Asia Pacific Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, USD mn 65

Figure 35. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66

Figure 36. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by MS Type, Value (USD mn) and Share (%) 67

Figure 37. Asia Pacific Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, USD mn 68

Figure 38. Asia Pacific Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, USD mn 69

Figure 39. Asia Pacific Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, USD mn 70

Figure 40. Asia Pacific Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, USD mn 71

Figure 41. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72

Figure 42. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 73

Figure 43. Asia Pacific Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, USD mn 74

Figure 44. Asia Pacific Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, USD mn 75

Figure 45. Asia Pacific Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, USD mn 76

Figure 46. Breakdown of APAC Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78

Figure 47. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value (USD mn) and Share (%) 79

Figure 48. Multiple Sclerosis Drugs Market in China, 2017-2027, USD mn 80

Figure 49. Multiple Sclerosis Drugs Market in Japan, 2017-2027, USD mn 83

Figure 50. Multiple Sclerosis Drugs Market in India, 2017-2027, USD mn 85

Figure 51. Multiple Sclerosis Drugs Market in Australia, 2017-2027, USD mn 87

Figure 52. Multiple Sclerosis Drugs Market in South Korea, 2017-2027, USD mn 89

Figure 53. Multiple Sclerosis Drugs Market in Rest of APAC, 2017-2027, USD mn 91

Figure 54. Growth Stage of Asia Pacific Multiple Sclerosis Drugs Industry over the Forecast Period 93


List of Table

Table 1. Snapshot of Asia Pacific Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 17

Table 2. Growth Rate of World GDP, 2020-2022 21

Table 3. World Health Spending by Region, USD bn, 2013-2020 28

Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 31

Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 32

Table 6. Main Product Trends and Market Opportunities in Asia Pacific Multiple Sclerosis Drugs Market 33

Table 7. Asia Pacific Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 41

Table 8. Asia Pacific Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, USD mn 44

Table 9. Asia Pacific Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, USD mn 46

Table 10. Asia Pacific Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, USD mn 47

Table 11. Asia Pacific Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, USD mn 58

Table 12. Asia Pacific Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 62

Table 13. Asia Pacific Multiple Sclerosis Drugs Market by MS Type, 2017-2027, USD mn 66

Table 14. Asia Pacific Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 72

Table 15. APAC Multiple Sclerosis Drugs Market by Country, 2017-2027, USD mn 78

Table 16. China Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 81

Table 17. China Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 81

Table 18. China Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 81

Table 19. Japan Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 84

Table 20. Japan Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 84

Table 21. Japan Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 84

Table 22. India Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 86

Table 23. India Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 86

Table 24. India Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 86

Table 25. Australia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 88

Table 26. Australia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 88

Table 27. Australia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 88

Table 28. South Korea Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, USD mn 90

Table 29. South Korea Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, USD mn 90

Table 30. South Korea Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, USD mn 90

Table 31. Multiple Sclerosis Drugs Market in Rest of APAC by Country/Region, 2017-2027, USD mn 92

Table 32. Abbvie, Inc.: Company Snapshot 97

Table 33. Abbvie, Inc.: Business Segmentation 97

Table 34. Abbvie, Inc.: Product Portfolio 98

Table 35. Abbvie, Inc.: Revenue, 2017-2019, USD mn 98

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022